Try Fund Library Premium
Free with a 30 day trial!
Gain access to
- Unlimited Watchlists
- Advanced Search Filtering
- Fund Comparisons
- Portfolio Scenarios
- Customizable PDF Reports
- Portfolio Rebalancer new
iShares Genomics Immunology and Healthcare Index ETF (XDNA : TSX)
Health Care Equity
Click for more information on Fundata’s FundGrade
FundGrade A
Click for more information on Fundata’s FundGrade.
|
Close (07-10-2026) |
$49.15 |
|---|---|
| Change |
-$1.31
(-2.60%)
|
| Open | $50.70 |
|---|---|
| Day Range | $48.94 - $50.70 |
| Volume | 363 |
As at June 30, 2026
As at June 30, 2026
Loading......
Loading......
Legend
Compare Options
Fund Returns
Inception Return (April 26, 2022): 5.64%
| Row Heading | Return | Annualized Return | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mth | 3 Mth | 6 Mth | YTD | 1 Yr | 2 Yr | 3 Yr | 4 Yr | 5 Yr | 6 Yr | 7 Yr | 8 Yr | 9 Yr | 10 Yr | |
| Fund | 16.14% | 19.62% | 33.44% | 33.44% | 72.02% | 23.70% | 16.64% | 7.07% | - | - | - | - | - | - |
| Benchmark | 7.68% | 8.56% | 5.60% | 5.60% | 20.56% | 7.33% | 9.46% | 9.21% | 6.48% | 7.57% | 9.16% | 9.16% | 9.22% | 9.36% |
| Category Average | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Category Rank | 1 / 55 | 2 / 55 | 1 / 53 | 1 / 53 | 1 / 53 | 2 / 52 | 2 / 50 | 21 / 43 | - | - | - | - | - | - |
| Quartile Ranking | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | - | - | - | - | - | - |
Monthly Return
| Return % | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | 5.24% | 3.08% | 7.87% | 8.44% | 7.90% | -5.85% | 7.68% | 9.50% | -5.39% | -0.01% | 3.01% | 16.14% |
| Benchmark | -0.60% | 4.16% | 2.38% | 3.42% | 7.21% | -2.85% | 0.25% | 3.41% | -6.17% | -2.20% | 3.08% | 7.68% |
Best Monthly Return Since Inception
16.14% (June 2026)
Worst Monthly Return Since Inception
-10.13% (December 2022)
Calendar Return (%)
| Return % | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | - | - | - | - | - | - | - | -10.47% | 7.46% | 11.64% |
| Benchmark | -8.68% | 14.01% | 11.82% | 17.06% | 13.59% | 15.28% | -1.72% | 1.42% | 9.95% | 9.64% |
| Category Average | - | - | - | - | - | - | - | - | - | - |
| Quartile Ranking | - | - | - | - | - | - | - | 4 | 3 | 2 |
| Category Rank | - | - | - | - | - | - | - | 43/ 43 | 26/ 50 | 17/ 52 |
Best Calendar Return (Last 10 years)
11.64% (2025)
Worst Calendar Return (Last 10 years)
-10.47% (2023)
Asset Allocation
| Name | Percent |
|---|---|
| US Equity | 61.10 |
| International Equity | 36.88 |
| Canadian Equity | 2.03 |
| Other | -0.01 |
Sector Allocation
| Name | Percent |
|---|---|
| Healthcare | 95.90 |
| Other | 4.10 |
Geographic Allocation
| Name | Percent |
|---|---|
| North America | 63.13 |
| Europe | 28.89 |
| Asia | 6.29 |
| Other | 1.69 |
Top Holdings
| Name | Percent |
|---|---|
| Twist Bioscience Corp | 5.19 |
| Moderna Inc | 5.15 |
| Bayer AG Cl N | 4.62 |
| Revolution Medicines Inc | 4.38 |
| Genmab A/S | 3.89 |
| Vertex Pharmaceuticals Inc | 3.88 |
| Incyte Corp | 3.87 |
| Merck & Co Inc | 3.71 |
| Ipsen SA | 3.69 |
| BioNTech SE - ADR | 3.69 |
Equity Style
Fixed Income Style
Risk vs Return (3 Yr)
iShares Genomics Immunology and Healthcare Index ETF
Median
Other - Health Care Equity
3 Yr Annualized
| Standard Deviation | 22.06% | - | - |
|---|---|---|---|
| Beta | 1.32% | - | - |
| Alpha | 0.05% | - | - |
| Rsquared | 0.51% | - | - |
| Sharpe | 0.65% | - | - |
| Sortino | 1.20% | - | - |
| Treynor | 0.11% | - | - |
| Tax Efficiency | 99.05% | - | - |
| Volatility |
|
- | - |
Risk Rating
Annualized Key Ratio Period Comparison
| Key Ratio | 1 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|
| Standard Deviation | 21.86% | 22.06% | - | - |
| Beta | 1.28% | 1.32% | - | - |
| Alpha | 0.32% | 0.05% | - | - |
| Rsquared | 0.69% | 0.51% | - | - |
| Sharpe | 2.53% | 0.65% | - | - |
| Sortino | 6.57% | 1.20% | - | - |
| Treynor | 0.43% | 0.11% | - | - |
| Tax Efficiency | 99.78% | 99.05% | - | - |
Fund Details
| Start Date | April 26, 2022 |
|---|---|
| Instrument Type | Exchange Traded Fund |
| Share Class | Do-It-Yourself |
| Legal Status | Trust |
| Sales Status | Open |
| Currency | CAD |
| Distribution Frequency | Semi Annual |
| Assets ($mil) | $9 |
| 52 Week High | $52.05 |
| 52 Week Low | $29.85 |
| Annual Dividend | $0.12 |
| Annual Yield | - |
| Index | - |
| Shares Outstanding | - |
| Registered Plan Eligible | Yes |
ETF Characteristics
| Exposure | - |
|---|---|
| Asset Class High | - |
| Asset Class Medium | - |
| Asset Class Low | - |
| Leveraged | - |
| Inverse | - |
| Advisor Series | - |
| Covered Call Strategy | No |
Investment Objectives
XDNA seeks to provide long-term capital growth by replicating, to the extent possible, the performance, net of expenses, of an Index selected at the discretion of BlackRock Canada that is composed of securities of issuers that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determined by the Index Provider. XDNA currently seeks to replicate the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index.
Investment Strategy
XDNA's current principal investment strategy is to employ a Replicating Strategy. In addition to or as an alternative to this strategy, XDNA may also invest by employing a Sampling Strategy, by investing in one or more iShares ETFs and/or through the use of derivatives. More information on these investment strategies and additional investment strategies that may be used by BlackRock Canada and/or BTC in managing this iShares Fund can be found under the heading Investment Strategies .
Portfolio Management
| Portfolio Manager |
BlackRock Asset Management Canada Limited |
|---|---|
| Sub-Advisor |
BlackRock Institutional Trust Company, N.A.
|
Management and Organization
| Fund Manager |
BlackRock Asset Management Canada Limited |
|---|---|
| Custodian |
- |
| Registrar |
- |
| Distributor |
- |
Fees
| MER | 0.44% |
|---|---|
| Management Fee | 0.39% |
Try Fund Library Premium
Free with a 30 day trial!
Gain access to
- Unlimited Watchlists
- Advanced Search Filtering
- Fund Comparisons
- Portfolio Scenarios
- Customizable PDF Reports
- Portfolio Rebalancer new
